<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01229098</url>
  </required_header>
  <id_info>
    <org_study_id>LEO 80185-G24</org_study_id>
    <nct_id>NCT01229098</nct_id>
  </id_info>
  <brief_title>Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris</brief_title>
  <official_title>A Phase 2 Maximal Use Systemic Exposure Study Evaluating the Safety and Efficacy of Calcipotriol 50 mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Gel Applied Once Daily in Subjects With Extensive Psoriasis Vulgaris on the Scalp and Non-scalp Regions of the Body (Trunk and/or Limbs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of once daily use of LEO 80185 gel on the&#xD;
      hypothalamic-pituitary-adrenal (HPA) axis and calcium metabolism in subjects with extensive&#xD;
      psoriasis vulgaris.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>Subjects with serum cortisol concentration of ≤18 mcg/dl at 30 minutes after ACTH-challenge [ Time Frame: Week 4 and week 8 ] [ Designated as safety issue: Yes ]&#xD;
Change in albumin-corrected serum calcium from baseline [ Time Frame: Week 4 and week 8 ] [ Designated as safety issue: Yes ]&#xD;
Change in 24-hour urinary calcium excretion from baseline [ Time Frame: Week 4 and week 8 ] [ Designated as safety issue: Yes ]&#xD;
Change in urinary calcium:creatinine ratio from baseline [ Time Frame: Week 4 and week 8 ] [ Designated as safety issue: Yes ]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>Subjects with &quot;Controlled disease&quot; (i.e., &quot;Clear&quot; or &quot;Almost clear&quot;) according to the investigator's global assessment of disease severity [ Time Frame: Weeks 2, 4, 8 ] [ Designated as safety issue: No ]&#xD;
Pharmacokinetic parameters for calcipotriol, betamethasone dipropionate and any metabolites.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>LEO 80185</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)</intervention_name>
    <description>LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel) Topical suspension applied once daily for up to 8 weeks</description>
    <arm_group_label>LEO 80185</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated informed consent obtained following receipt of verbal and written&#xD;
             information about the study prior to any trial related activities (including any&#xD;
             wash-out period).&#xD;
&#xD;
          2. Age 18 years or above.&#xD;
&#xD;
          3. Either sex.&#xD;
&#xD;
          4. Any race or ethnicity.&#xD;
&#xD;
          5. Attending a hospital out-subject clinic or the private practice of a dermatologist for&#xD;
             treatment of psoriasis vulgaris.&#xD;
&#xD;
          6. Clinical diagnosis of psoriasis vulgaris involving non scalp regions of the body&#xD;
             (trunk and/or limbs) with or without involvement of the scalp.&#xD;
&#xD;
          7. At SV2 and Day 0 (Visit 1) a clinical diagnosis of psoriasis vulgaris which is:&#xD;
&#xD;
               -  amenable to topical treatment with a maximum of 100 g of study medication per&#xD;
                  week, and&#xD;
&#xD;
               -  of an extent of between 15 and 30% of the body surface area (BSA) excluding&#xD;
                  psoriasis on the face, genitals or skin folds.&#xD;
&#xD;
               -  a disease severity on the trunk and/or limbs graded as at least moderate&#xD;
                  according to the investigator's global assessment (IGA)&#xD;
&#xD;
          8. Subjects with normal HPA axis function at SV2 including a serum cortisol concentration&#xD;
             above 5 mcg/dL before ACTH challenge test and above 18 mcg/dL 30 minutes after ACTH&#xD;
             challenge test.&#xD;
&#xD;
          9. Albumin-corrected serum calcium, below the upper reference limit at SV2.&#xD;
&#xD;
         10. Females of child-bearing potential must have a negative urine pregnancy test result at&#xD;
             baseline Visit SV2 and must agree to use a highly effective method of contraception&#xD;
             during the study. Highly effective methods are defined as ones which results in a low&#xD;
             failure rate (less than 1% per year) such as progestin-only formulations (implants,&#xD;
             injectables), some intra-uterine devices, or vasectomised partner. Subjects must have&#xD;
             used the contraceptive method continuously for at least 1 month prior to the pregnancy&#xD;
             test and must continue using the contraceptive method for at least 1 week after the&#xD;
             last application of study medication (or until study visit FU2 if applicable). A&#xD;
             female is defined as not of child-bearing potential if she is postmenopausal (12&#xD;
             months with no menses without an alternative medical cause), or surgically sterile&#xD;
             (tubal ligation/section, hysterectomy or bilateral ovariectomy).&#xD;
&#xD;
         11. Able to communicate with the investigator and understand and comply with the&#xD;
             requirements of the study.&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
         12. A history of serious allergy, allergic asthma or serious allergic skin rash&#xD;
&#xD;
         13. Known or suspected hypersensitivity to any medication (including&#xD;
             ACTH/cosyntropin/tetracosactide) or to any component of the LEO 80185 gel or&#xD;
             CORTROSYN.&#xD;
&#xD;
         14. Systemic treatment with corticosteroids (including inhaled and nasal steroids) within&#xD;
             12 weeks prior to SV2 and during the study.&#xD;
&#xD;
         15. Systemic treatment with biological therapies (marketed or not marketed), with a&#xD;
             possible effect on psoriasis vulgaris within the following time period prior to Day 0&#xD;
             (Visit 1) and during the study:&#xD;
&#xD;
               -  etanercept - within 4 weeks prior to Visit 1&#xD;
&#xD;
               -  adalimumab, alefacept, infliximab -within 2 months prior to Visit 1&#xD;
&#xD;
               -  ustekinumab, briakinumab - within 4 months prior to Visit 1&#xD;
&#xD;
               -  experimental products - within 4 weeks/5 half-lives (whichever is longer) prior&#xD;
                  to Visit 1&#xD;
&#xD;
         16. Systemic treatment with therapies other than biologicals, with a possible effect on&#xD;
             psoriasis vulgaris (e.g., retinoids, methotrexate, immunosuppressants) within 4 weeks&#xD;
             prior to Visit 1 (Day 0) or during the study.&#xD;
&#xD;
         17. PUVA or Grenz ray therapy within 4 weeks prior to Visit 1 (Day 0) or during the study&#xD;
&#xD;
         18. UVB therapy within 2 weeks prior to Visit 1 (Day 0) or during the study.&#xD;
&#xD;
         19. Topical treatment with corticosteroids or vitamin D analogues (calcipotriol,&#xD;
             calcitriol or tacalcitol) on any body location within 2 weeks prior to SV2 or during&#xD;
             the study.&#xD;
&#xD;
         20. Any topical treatment of psoriasis vulgaris on the scalp or trunk and/or limbs (except&#xD;
             for emollients and non-steroid medicated shampoos) within 2 weeks prior to Visit 1&#xD;
             (Day 0) or during the study.&#xD;
&#xD;
         21. Oral calcium supplements, vitamin D supplements, antacids, thiazide and/or loop&#xD;
             diuretics, antiepileptics, diphosphonates or calcitonin within 4 weeks prior to SV2&#xD;
             and during the study. Note: Stable doses of oral vitamin D supplementation ≤400 IU/day&#xD;
             is permitted provided there are no dose adjustments during the study period.&#xD;
&#xD;
         22. Planned initiation of, or changes to, concomitant medication that could affect&#xD;
             psoriasis vulgaris (e.g., betablockers, antimalarials, lithium, ACE inhibitors) during&#xD;
             the study.&#xD;
&#xD;
         23. Planned excessive exposure of treated areas to either natural or artificial sunlight&#xD;
             (e.g. sunlamps etc.) during the study that may affect the psoriasis vulgaris.&#xD;
&#xD;
         24. Oestrogen therapy (including contraceptives) or any other medication known to affect&#xD;
             cortisol levels or HPA axis integrity within 4 weeks prior to SV2 or during the study.&#xD;
&#xD;
         25. Cytochrome P450 3A4 (CYP 3A4) inducers (e.g., barbiturates, phenytoin, rifampicin)&#xD;
             within 4 weeks prior to SV2 or during the study.&#xD;
&#xD;
         26. Systemic or topical cytochrome P450 3A4 (CYP 3A4) inhibitors (e.g., ketoconazole,&#xD;
             itraconazole, metronidazole) within 4 weeks prior to SV2 or during the study. Topical&#xD;
             ketoconazole within 2 weeks prior to SV2.&#xD;
&#xD;
         27. Hypoglycaemic sulfonamides within 4 weeks prior to the SV2 or during the study.&#xD;
&#xD;
         28. Antidepressant medications within 4 weeks prior to SV2 or during the study.&#xD;
&#xD;
         29. Not following nocturnal sleep patterns (e.g. night shift workers are excluded).&#xD;
&#xD;
         30. Known or suspected endocrine disorder that may affect the results of the ACTH&#xD;
             challenge test.&#xD;
&#xD;
         31. Clinical signs or symptoms of Cushing's disease or Addison's disease.&#xD;
&#xD;
         32. Known or suspected diabetes mellitus.&#xD;
&#xD;
         33. Known or suspected cardiac disorders associated with abnormal QT intervals or rhythm&#xD;
             disturbances including clinically significant bradycardia or tachycardia.&#xD;
&#xD;
         34. Known or suspected severe renal insufficiency or severe hepatic disorders.&#xD;
&#xD;
         35. Known or suspected disorders of calcium metabolism associated with hypercalcaemia.&#xD;
&#xD;
         36. Any clinically significant abnormality following review of screening laboratory tests&#xD;
             (blood and spot urine samples), physical examination or blood pressure/heart rate&#xD;
             measurement performed at SV2.&#xD;
&#xD;
         37. Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis.&#xD;
&#xD;
         38. Any of the following conditions present on the study treatment areas: viral (e.g.,&#xD;
             herpes or varicella) lesions of the skin, fungal and bacterial skin infections,&#xD;
             parasitic infections, skin manifestations in relation to syphilis or tuberculosis,&#xD;
             rosacea, acne vulgaris, acne rosacea, atrophic skin, striae atrophicae, fragility of&#xD;
             skin veins, ichthyosis, ulcers and wounds.&#xD;
&#xD;
         39. Other inflammatory skin diseases that may confound the evaluation of psoriasis&#xD;
             vulgaris (e.g. seborrhoeic dermatitis, contact dermatitis and cutaneous mycosis).&#xD;
&#xD;
         40. Current participation in any other interventional clinical trial.&#xD;
&#xD;
         41. Previously enrolled in this trial (with the exception of subjects excluded due to&#xD;
             hypocalcaemia prior to implementation of Consolidated Clinical Study Protocol 2).&#xD;
&#xD;
         42. Received any non-marketed drug substance (i.e., an agent which has not yet been made&#xD;
             available for clinical use following registration) within 4 weeks or 5 half-lives&#xD;
             (whichever is longer) prior to SV1.&#xD;
&#xD;
         43. Known or suspected of not being able to comply with the trial protocol (e.g.,&#xD;
             alcoholism, drug dependency or psychotic state).&#xD;
&#xD;
         44. Females who are pregnant, have a positive urine pregnancy test at baseline Visit SV2,&#xD;
             or are breast-feeding. Females of child-bearing potential and wishing to become&#xD;
             pregnant during the study or not using an adequate method of contraception during the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shane Silver, MB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermadvances Research, 203 Edmonton Street, Winnipeg, Manitoba R3C 1R4 Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Winnipeg Clinic</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 0N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermadvances Research</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 1R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpha Clinical Research Centre</name>
      <address>
        <city>Saint John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 4S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newlab Clinical Research</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1C 2H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Canada Cutaneous Research Associates Ltd.</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermsearch</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5X 2P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc.</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Cosmetic and Laser Surgery</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 7W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Co-Medica Research Network Inc.</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1E 3C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oshawa Clinic</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1H 1B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>October 26, 2010</study_first_submitted>
  <study_first_submitted_qc>October 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2010</study_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

